August 03, 2026

Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population

June 17, 2026

Cyclo Therapeutics has announced that the final patient has now completed their last visit in the Phase 3 TransportNPC™ clinical study, which is evaluating the investigational therapy Trappsol® Cyclo™. This milestone represents the completion of the active treatment phase of the study and brings researchers one step closer to understanding whether this therapy could play a role in treating NPC. For individuals and families living with the condition, reaching this stage is an important moment, reflecting both progress in research and continued momentum towards potential new treatment options.